Hard-fought approval to commercial flop: Uniqure pulling plug on first gene therapy – BioWorld Online
|
Hard-fought approval to commercial flop: Uniqure pulling plug on first gene therapy
BioWorld Online LONDON – Uniqure NV is ditching its world-first gene therapy Glybera and will not renew the European license when it expires on Oct. 25. If that is a sad end to one of the most protracted drug development sagas in history, it undoubtedly sets a bad … |
